CALGARY, Alberta, Aug. 29, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company ...
SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC) ...
Micot (Suzhou) Technology Co. Ltd. has disclosed xanthine derivatives reported to be useful for the treatment of hypertension and asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback